Aspirin Suppository
Brand names: Aspirin
Category: Analgesia/Addiction, Cardiovascular
FDA status: To Be Discontinued · Last FDA update: Jul 23, 2026 · First posted: Jul 23, 2026 · 1 manufacturers, 1 listed presentations
As of Jul 23, 2026, the FDA lists Aspirin Suppository as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Aspirin, Suppository, 300 mg (NDC 0574-7034-12) NDC 0574-7034-12 |
Padagis US LLC | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Analgesia/Addiction, Cardiovascular medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Aspirin Suppository (FDA data as of Jul 23, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Aspirin Suppository. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/aspirin-suppository.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).